Trial · NCT00102440
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL) | Febuxostat 80 mg QD | 53 | Percentage of subjects | ||
| Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL) | Febuxostat 120 mg QD | 62 | Percentage of subjects | ||
| Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL) | Allopurinol 300 mg QD | 21 | Percentage of subjects | ||
| Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 28 Visit | Febuxostat 80 mg QD | 72 | Percentage of subjects | ||
| Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 28 Visit | Febuxostat 120 mg QD | 82 | Percentage of subjects | ||
| Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 28 Visit | Allopurinol 300 mg QD | 42 | Percentage of subjects | ||
| Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 52 Visit | Febuxostat 80 mg QD | 81 | Percentage of subjects | ||
| Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 52 Visit | Febuxostat 120 mg QD | 82 | Percentage of subjects | ||
| Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 52 Visit | Allopurinol 300 mg QD | 39 | Percentage of subjects | ||
| Percentage of Subjects With Serum Urate <6.0 mg/dL at Final Visit | Febuxostat 80 mg QD | 74 | Percentage of subjects | ||
| Percentage of Subjects With Serum Urate <6.0 mg/dL at Final Visit | Febuxostat 120 mg QD | 80 | Percentage of subjects | ||
| Percentage of Subjects With Serum Urate <6.0 mg/dL at Final Visit | Allopurinol 300 mg QD | 36 | Percentage of subjects | ||
| Percent Change From Baseline in Serum Urate Levels at Week 28. | Febuxostat 80 mg QD | -46.3 | Standard Deviation 15.76 | percent change from baseline | |
| Percent Change From Baseline in Serum Urate Levels at Week 28. | Febuxostat 120 mg QD | -53.5 | Standard Deviation 18.20 | percent change from baseline | |
| Percent Change From Baseline in Serum Urate Levels at Week 28. | Allopurinol 300 mg QD | -34.8 | Standard Deviation 12.92 | percent change from baseline | |
| Percent Change From Baseline in Serum Urate Levels at Week 52. | Febuxostat 80 mg QD | -47.7 | Standard Deviation 17.50 | percent change from baseline | |
| Percent Change From Baseline in Serum Urate Levels at Week 52. | Febuxostat 120 mg QD | -53.0 | Standard Deviation 19.31 | percent change from baseline | |
| Percent Change From Baseline in Serum Urate Levels at Week 52. | Allopurinol 300 mg QD | -34.8 | Standard Deviation 13.56 | percent change from baseline | |
| Percent Change From Baseline in Serum Urate Levels at Final Visit | Febuxostat 80 mg QD | -44.7 | Standard Deviation 19.10 | percent change from baseline | |
| Percent Change From Baseline in Serum Urate Levels at Final Visit | Febuxostat 120 mg QD | -51.5 | Standard Deviation 19.91 | percent change from baseline |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00102440/results